Combined metallothioneins and p53 proteins expression as a prognostic marker in patients with Dukes stage B and C colorectal cancer

Human Pathology

Volumn 43, Issue 10, 2012, Pages 1695-1703

  Arriaga, J M ^a   Bravo, I A ^b   Bruno, L ^a   Morales Bayo, S ^c   Hannois, A ^b   Sanchez Loria, F ^a   Pairola, F ^a   Huertas, E ^a   Roberti, M P ^a   Rocca, Y S ^a   Aris, M ^d   Barrio, M M ^a   Baffa Trasci, S ^a   Levy, E M ^a   Mordoh, J ^a,d   Bianchini, M ^a  

^a Instituto Médico Especializado Alexander Fleming   (Argentina)

^b Hospital Interzonal General Agudos Eva Peron   (Argentina)

^c Hospital Municipal Prof Dr Houssay   (Argentina)

^d FUNDACIÓN INSTITUTO LELOIR   (Argentina)

Author keywords

Colorectal cancer; Metallothioneins; p53; Prognostic markers

Indexed keywords

METALLOTHIONEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DUKES STAGE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION;

COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; METALLOTHIONEIN; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866504471     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.12.014     Document Type: Article

References (25)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. C.C. Compton, L.P. Fielding, and L.J. Burgart Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999 Arch Pathol Lab Med 124 2000 979 994 (Pubitemid 30602039)
3. L. Sobin, and C. Wittekind TNM classification of malignant tumours 2002 Wiley-Liss New York 100 105
4. E. Van Cutsem, C.H. Köhne, and I. Láng Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 2011 2011 2019
5. C.M. Ribic, D.J. Sargent, and M.J. Moore Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer N Engl J Med 349 2003 247 257 (Pubitemid 36859476)
6. D.J. Sargent, S. Marsoni, and G. Monges Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer J Clin Oncol 28 2010 3219 3226
7. F.A. Sinicrope, N.R. Foster, and S.N. Thibodeau DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy J Natl Cancer Inst 103 2011 863 875
8. A.K. West, R. Stallings, C.E. Hildebrand, R. Chiu, M. Karin, and R.I. Richards Human metallothionein genes: structure of the functional locus at 16q13 Genomics 8 1990 513 518
9. D. Ofner, H. Maier, and B. Riedmann Immunohistochemical metallothionein expression in colorectal adenocarcinoma: correlation with tumour stage and patient survival Virchows Arch 425 1994 491 497
10. J.M. Arriaga, E.M. Levy, and A.I. Bravo Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival Hum Pathol 2011 10.1016/j.humpath.2011.04.015
11. A.J. Levine p53, the cellular gatekeeper for growth and division Cell 88 1997 323 331 (Pubitemid 27131374)
12. T. Miyashita, and J.C. Reed Tumor suppressor p53 is a direct transcriptional activator of the human bax gene Cell 80 1995 293 299
13. C.C. Harris, and M. Hollstein Clinical implications of the p53 tumor-suppressor gene N Engl J Med 329 1993 1318 1327 (Pubitemid 23317333)
14. B.M. Kerns, P.A. Jorda, and M.H. Moore p53 overexpression in formalin-fixed, paraffin-embedded tissues detected by immunohistochemistry J Histochem Cytochem 40 1992 1047 1051
15. J.P. Kruse, and W. Gu Modes of p53 regulation Cell 137 2009 609 622
16. R. Puca, L. Nardinocchi, and G. Bossi Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc Exp Cell Res 315 2009 67 75
17. C. Méplan, M.J. Richard, and P. Hainaut Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells Oncogene 19 2000 5227 5236
18. E.A. Ostrakhovitch, P.E. Olsson, S. Jiang, and M.G. Cherian Interaction of metallothionein with tumor suppressor p53 protein FEBS Lett 580 2006 1235 1238 (Pubitemid 43221983)
19. E.A. Ostrakhovitch, P.E. Olsson, J. von Hofsten, and M.G. Cherian P53 mediated regulation of metallothionein transcription in breast cancer cells J Cell Biochem 102 2007 1571 1583 (Pubitemid 350223957)
20. L.Z. Fan, and M.G. Cherian Potential role of p53 on metallothionein induction in human epithelial breast cancer cells Br J Cancer 87 2002 1019 1026 (Pubitemid 35305656)
21. R. Hamelin, P. Laurent-Puig, and S. Olshwang Association of p53 mutations with short survival in colorectal cancer Gastroenterology 106 1994 42 48 (Pubitemid 24011863)
22. W. Remmele, and H.E. Stegner Vorschlag zur eincheitlichen Definition eines Immunoreaktiven Score (IRS) für den immunohistochemischen Ostrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe Der Pathologe 8 1987 138 140
23. B. Vogelstein, E.R. Fearon, and S.R. Hamilton Genetic alterations during colorectal-tumor development N Engl J Med 319 1988 525 532
24. W.S. Samowitz, K. Curtin, and K.N. Ma Prognostic significance of p53 mutations in colon cancer at the population level Int J Cancer 99 2002 597 602 (Pubitemid 34461615)
25. M. Olivier, M. Hollstein, and P. Hainaut TP53 mutations in human cancers: origins, consequences, and clinical use Cold Spring Harb Perspect Biol 2 2010 a001008